Mirvetuximab (Anti-FOLR1)

Mirvetuximab (Anti-FOLR1) is a chimeric monoclonal antibody of IgG1 subtype targeting FOLR1 (folate receptor 1). The antibody-drug conjugate (ADC) Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This ADC drug is a conjugate that combines a monoclonal antibody Mirvetuximab, linker and microtubule inhibitor (DM4). This biosimilar antibody is used for research only. MW: 145.2 KD.

Product Details
Species Reactivity	Human
Host/Isotype	Human IgG1
Class	Monoclonal
Type	Recombinant Antibody
Immunogen	Human FOLR1 (folate receptor 1)
Clone	Mirvetuximab biosimilar
Conjugate	Unconjugated
Purity	99%
Molecular Weight	145.2 KD
Protein Concentration	1mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100mM Pro-Ac, 20mM Arg-Ac, pH 5.0